Stay updated on Pembrolizumab for Metastatic TNBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Metastatic TNBC Clinical Trial page.

Latest updates to the Pembrolizumab for Metastatic TNBC Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.8%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check46 days agoChange DetectedThe page has removed detailed descriptions of a clinical trial for pembrolizumab in metastatic triple-negative breast cancer, including inclusion and exclusion criteria, while adding a new version number and identifiers related to the study.SummaryDifference17%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check60 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check89 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
Stay in the know with updates to Pembrolizumab for Metastatic TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Metastatic TNBC Clinical Trial page.